バイオシミュレーションの世界市場

visiongainが発行した調査報告書(VGAIN7081167)
◆英語タイトル:Biosimulation World Market 2017-2027
◆商品コード:VGAIN7081167
◆発行会社(リサーチ会社):visiongain
◆発行日:2017年6月
◆ページ数:148
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥349,860見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥419,860見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥699,860見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

visiongain社が発行した当調査レポートでは、バイオシミュレーションの世界市場について調査・分析し、バイオシミュレーションの世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・バイオシミュレーションの世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・バイオシミュレーションの世界市場:セグメント別市場分析
・バイオシミュレーションの世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

Biosimulation – our new study reveals trends, R&D progress, and predicted revenues
Where is the Biosimulation market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 148-page report provides 112 tables, charts, and graphs, providing over 1700 unique datapoints. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biosimulation market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are forecasts for 2 Service Types, 5 Biosimulation software products, 6 software applications and 4 biosimulation end-users

Biosimulation Software, by Product
• PK/PD
• Molecular
• Toxicity
• PBPK
• Trial Design

Biosimulation Services
• In-House
• External / Contract

Biosimulation, by Application
• Drug Development
• Preclinical Testing
• ADME/Tox
• PK/PD
• Clinical Trials
• Drug Discovery

Biosimulation, by End User
• Pharmaceutical and Biotechnology Companies
• Contract Research Organisations (CROs)
• Academic & Government
• Regulatory Authorities

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 11 leading national markets:
• North America:
• The US
• Canada
• Mexico

• Europe:
• Germany
• Italy
• Spain
• France
• Russia
• RoE

• APAC:
• Japan
• China
• India
• RoA

• RoW

The report also includes profiles and forecasts for some of the leading companies in the Biosimulation market, with a focus on the Biosimulation segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Germany, France and China in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth
Overall world revenue for Biosimulation will surpass $1.2bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing cost of drug development and increasing need for simulation software to reduce

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biosimulation Market report helps you
In summary, our 125-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Biosimulation market and 3 different segmentations, with forecasts for 2 Services, 5 Products, 6 Applications and 4 End Users – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 11 of the leading national markets – US, Canada, Mexico, Germany, France, Italy, Spain, Russia, Japan, China, India,
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market – including company profiles and forecasts for 10 companies’ biosimulation segment revenues to 2027

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today Biosimulation World Market 2017-2027: Revenue Prospects by Product (PK/PD, Molecular, Toxicity, PBPK, Trial Design), Services (In-House, External), Application (Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials, Drug Discovery, End User (Pharmaceutical and Biotechnology Companies, CROs, Academic & Government, Regulatory Authorities) and Geography. Avoid missing out – get our report now.

【レポートの目次】

1. Report Overview
1.1 Global Biosimulation Market Overview
1.2 Why You Should Read This Report
1.3 Key Questions Answered by This Analytical Report
1.4 Who is This Report For?
1.5 Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain

2. Introduction to Biosimulation
2.1 What is Biosimulation?
2.2 Classification of Biosimulation

3. Biosimulation: World Market by Product 2017-2027
3.1 Biosimulation Software Submarket Forecast & Analysis 2017-2027
3.2 PK/PD Modelling and Simulation Software
3.2.1 Molecular Modelling and Simulation Software
3.2.2 Toxicity Prediction Software
3.2.3 PBPK Modelling and Simulation Software
3.2.4 Trial Design Software
3.2.5 Other Software
3.3 Biosimulation Services Submarket Forecast & Analysis 2017-2027
3.3.1 In-House Services
3.3.2 External/Contract Services

4. Biosimulation: World Market by Application 2017-2027
4.1 Drug Development Submarket Forecast & Analysis 2017-2027
4.1.1 Preclinical Testing Submarket Forecast & Analysis 2017-2027
4.1.1.1 ADME/Tox Submarket Forecast & Analysis 2017-2027
4.1.1.2 PK/PD Submarket Forecast & Analysis 2017-2027
4.1.2 Clinical Trials Submarket Forecast & Analysis 2017-2027
4.2 Drug Discovery Submarket Forecast & Analysis 2017-2027
4.2.1 Target Identification and Validation Submarket Forecast & Analysis 2017-2027
4.2.2 Lead Identification and Optimization Submarket Forecast & Analysis 2017-2027
4.3 Other Applications Submarket Forecast & Analysis 2017-2027

5. Biosimulation: World Market by End Users 2017-2027
5.1 Pharmaceutical and Biotechnology Companies
5.2 Contract Research Organizations
5.3 Academic and Government Research Institutes
5.4 Regulatory Authorities
5.5 Others

6. Regional Biosimulation Market Forecasts 2017-2027
6.1 Regional Biosimulation Market Forecasts 2017-2027
6.2 North American Biosimulation Market Forecasts 2017-2027
6.2.1 USA Biosimulation Market Forecasts 2017-2027
6.2.2 Canada Biosimulation Market Forecasts 2017-2027
6.2.3 Mexico Biosimulation Market Forecasts 2017-2027
6.3 European Biosimulation Market Forecasts 2017-2027
6.3.1 Germany Biosimulation Market Forecasts 2017-2027
6.3.2 France Biosimulation Market Forecasts 2017-2027
6.3.3 Italy Biosimulation Market Forecasts 2017-2027
6.3.4 Spain Biosimulation Market Forecasts 2017-2027
6.3.5 Russia Biosimulation Market Forecasts 2017-2027
6.3.6 Rest of Europe Biosimulation Market Forecasts 2017-2027
6.4 Asia-Pacific Biosimulation Market Forecasts 2017-2027
6.4.1 China Biosimulation Market Forecasts 2017-2027
6.4.2 India Biosimulation Market Forecasts 2017-2027
6.4.3 Japan Biosimulation Market Forecasts 2017-2027
6.4.4 Rest of Asia-Pacific Biosimulation Market Forecasts 2017-2027
6.5 RoW Biosimulation Market Forecasts 2017-2027

7. Qualitative Analysis of Biosimulation Market
7.1 SWOT Analysis
7.2 Strengths
7.2.1 Reduction in Drug Discovery and Development Costs
7.2.2 Introduction of New Products
7.2.3 Opportunities
7.2.4 Increased Demand from the Pharmaceutical Industry
7.2.5 Increased Need for Ethical Practices in R&D
7.3 Weaknesses
7.3.1 Issues with Prediction Accuracy
7.3.2 Lack of Sufficient Technical Expertise and Supporting Infrastructure
7.3.3 Threats
7.3.4 High R&D Costs
7.3.5 Undefined Regulations
7.4 Porter’s Five Forces Analysis of the Biosimulation Market
7.4.1 Rivalry among Competitors [High] 7.4.2 Threat of New Entrants [Medium] 7.4.3 Power of Suppliers [Low] 7.4.4 Power of Buyers [Medium] 7.4.5 Threat of Substitutes [Medium] 7.5 Drivers
7.5.1 Increasing investment in the R&D sector of the pharmaceutical and biotechnology industries
7.5.2 Increase in the technological advancements
7.5.3 Boost in the growth of pharmaceutical and biotechnology industries
7.5.4 Increase in the utilization of the personalized medicine coupled with growth in the biosimilars and biologics market
7.5.5 Increasing need to reduce the drug discovery and development cost
7.6 Restraints
7.6.1 Dearth of skilled workforce
7.6.2 Lack of standardization-A major hurdle for the biosimulation market growth

8. Leading Companies in The Biosimulation Market
8.1 Accelrys Inc
8.1.1 Accelrys Product Portfolio
8.1.2 Accelrys Sales Analysis
8.1.3 Key developments of Accelrys
8.2 Certara
8.2.1 Certara Product Portfolio
8.2.2 Certara Sales Analysis
8.2.3 Key developments of Certara
8.3 Simulation Plus Inc.
8.3.1 Simulation Plus Product Portfolio
8.3.2 Simulation Plus Sales Analysis
8.3.3 Key developments of Simulation Plus
8.4 Dassault Systems SA
8.4.1 Dassualt Systemes Product Portfolio
8.4.2 Dassualt SystemsSales Analysis
8.4.3 Key developments of Dassault Systems
8.5 Schrödinger INC.
8.5.1 Schrödinger Product Portfolio
8.5.2 Schrödinger Sales Analysis
8.5.3 Key developments of Schrödinger.
8.6 Advanced Chemistry Development, INC
8.6.1 Advanced Chemistry Development Product Portfolio
8.6.2 Advanced Chemistry Development Inc. Sales Analysis
8.6.3 Key developments of Advanced Chemistry Development
8.7 Chemical Computing Group
8.7.1 Chemical Computing Group Product Portfolio
8.7.2 Chemical Computing Group Sales Analysis
8.7.3 Key developments of Chemical Computing Group
8.8 Entelos Holding Corporation
8.8.1 Entelos Holding Corporation Product Portfolio
8.8.2 Entelos Holding Corporation Sales Analysis
8.8.3 Key developments of Entelos Holding Corporation
8.9 Genedata AG
8.9.1 Genedata AG Product Portfolio
8.9.2 Genedata AG Sales Analysis
8.9.3 Key developments of Genedata AG
8.10 Physiomics PLC
8.10.1 Physiomics Product Portfolio
8.10.2 Physiomics Sales Analysis
8.10.3 Key developments of Physiomics

9. Conclusions
9.1 Current Leading Biosimulation Segments
9.2 Leading Biosimulation Companies
9.3 Leading Regional Markets
9.4 Emerging Biosimulation Market segments
9.5 The Future of the Biosimulation Market?

10. Glossary

Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Figures
Figure 2.1 Global Biosimulation Market Segmentation Overview, 2017
Figure 3.1 Global Biosimulation Market Segmentation, By Type, 2017
Figure 3.2 Biosimulation software Submarkets share Analysis (%) 2016-2027
Figure 3.3 Biosimulation Regional Market Share Analysis (%), 2016
Figure 3.4 PK/PD Modelling and Simulation Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
Figure 3.5 Molecular Modelling and Simulation Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
Figure 3.6 Toxicity Prediction Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
Figure 3.7 PBPK Modelling and Simulation Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
Figure 3.8 Trial Design Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
Figure 3.9 Other Software Market Forecasts By Geography, Revenue Share Analysis (%), 2016-2027
Figure 3.10 Biosimulation Services Submarkets, Revenue Share Analysis (%), 2016-2027
Figure 3.11 In-House Biosimulation Services Market Forecast, By Geography, Revenue Share Analysis (%), 2016-2027
Figure 3.12 External Biosimulation Services Market Share Analysis, By Geography (%), 2016-2027
Figure 4.1 Global Biosimulation Market Share Analysis by Application (%), 2017 and 2027
Figure 4.2 Biosimulation Applications Market Forecasts ($m), 2016-2027
Figure 4.3 Drug Development Market Share Analysis, By Type(%) 2016-2027
Figure 4.4 Preclinical Testing Submarket Market Share Analysis, By Geography (%), 2016-2027
Figure 4.5 Preclinical Testing Submarket Forecast by Type, (%) 2017
Figure 4.6 ADME/Tox Drug Development Market Forecasts, By geography (%) 2016 vs. 2027
Figure 4.7 PK/PD Drug Development Market Share Analysis, By Geography (%) 2017
Figure 4.8 Clinical Trials Market Share Analysis (%), By Geography, 2017
Figure 4.9 Biosimulation Market Forecasts for Drug Discovery, Revenue Share Forecast (%) by Type 2016-2027
Figure 4.10 Target Identification and Validation Revenue Share Forecasts (%), By Geography 2017-2027
Figure 4.11 Lead Identification and Optimization Revenue Share Forecasts (%), By Geography 2017-2027
Figure 4.12 Other Applications Revenue Share Forecasts (%), By Geography 2017-2027
Figure 5.1 Biosimulation Market Forecasts, By End Users ($m, AGR%) 2016-2027
Figure 5.2 Pharmaceutical and Biotechnology Market Forecasts, By Geography (%) 2017
Figure 5.3 Contract research organizations Market Forecasts, By geography ($m, AGR%) 2017
Figure 5.4 Academic and Government Research Institutes Market Forecasts, By Geography (%) 2016-2027
Figure 5.5 Regulatory Authorities Market Forecasts, By Geography ($m, AGR%) 2017
Figure 6.1 Regional Biosimulation Markets Forecasts ($m, AGR%), 2016-2027
Figure 6.2 Regional Biosimulation Markets Forecasts ($m, AGR%), 2022-2027
Figure 6.3 North American Biosimulation Market Forecasts, by Country (%), 2017
Figure 6.4 US Biosimulation Market Forecasts ($m), 2016-2027
Figure 6.5 Canada Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.6 Mexico Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.7 European Biosimulation Revenue Share (%), 2016
Figure 6.8 Germany Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.9 France Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.10 Italy Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.11 Spain Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.12 Russia Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.13 Rest of Europe Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.14 Asia-Pacific Biosimulation Market Revenue Share (%), 2016
Figure 6.15 China Biosimulation Market Forecasts ($m, AGR%), 2016-2027
Figure 6.16 India Biosimulation Market Forecasts ($m, AGR%), 2022-2027
Figure 6.17 Japan Biosimulation Market Forecasts ($m, AGR%), 2022-2027
Figure 6.19 RoW Biosimulation Market Forecasts ($m, AGR%), 2017-2027
Figure 6.18 Rest of Asia-Pacific Biosimulation Market Forecasts ($m, AGR%), 2022-2027
Figure 7.1 Porter's Five Forces Analysis of the Biosimulation Market, 2075-2027
Figure 7.2 Biosimulation Market: Drivers and Restraints, 2017-2027

List of Tables
Table 3.1 Biosimulation Submarkets, by Type Forecast ($m, AGR%) 2016-2027
Table 3.2 Biosimulation Software Submarkets, Forecast ($m, AGR%) 2026-2027
Table 3.3 Biosimulation Software Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 3.4 PK/PD Modelling and Simulation Software Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 3.5 Molecular modelling and simulation software Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 3.6 Toxicity prediction software Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 3.7 PBPK Modelling and Simulation Software Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 3.8 Trial design Software Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 3.9 Other Software Market Forecasts, By Geography 2016-2027
Table 3.10 Biosimulation Services Submarkets Forecast ($m, AGR%) 2016-2027
Table 3.11 Biosimulation Services Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 3.12 In-House Biosimulation Services Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 3.13 External/Contract Biosimulation Services Market Forecasts, By Geography ($m, AGR %), 2016-2027
Table 4.1 Biosimulation Application Market Forecasts ($m, AGR %), 2016-2027
Table 4.2 Drug Development Market Forecasts, By Type ($m, AGR%) 2016-2027
Table 4.3 Drug Development Market Forecasts, By Geography ($m, AGR (%), CAGR (%)) 2016-2027
Table 4.4 Preclinical Testing Submarket Forecast by Type, ($m, AGR (%), CAGR (%))2016-2027
Table 4.5 ADME/Tox Drug Development Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 4.6 PK/PD Drug Development Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 4.7 Clinical Trials Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 4.8 Biosimulation Market Forecasts for Drug Discovery, By Type ($m, AGR (%), CAGR (%))2016-2027
Table 4.9 Biosimulation Market Forecasts for Drug Discovery, by Geography ($m, AGR (%), CAGR (%)) 2016-2027
Table 4.10 Target Identification and Validation Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 4.11 Lead Identification and Optimization Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 4.12 Other Applications Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 5.1 Biosimulation Market Forecasts, By End Users ($m, AGR (%), CAGR (%))2016-2027
Table 5.2Pharmaceutical and Biotechnology Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 5.3 Contract Research Organizations Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 5.4 Academic and Government Research Institutes Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 5.5: Some of the Major Regulatory Authorities Across the Globe
Table 5.6 Regulatory Authorities Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 5.7 Other End Users Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
Table 6.1 Leading National Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.2 Regional Biosimulation Market Forecasts ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.3 North American Biosimulation Market Forecasts by Country ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.4 US Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.5 Canadian Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.6 Mexican Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.7 European Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.8 German Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.9 France Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.10 Italy Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.11 Spain Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.12 Russia Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.13 Rest of Europe Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.14 Asia-Pacific Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.15 Chinese Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.16 Indian Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.17 Japanese Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.18 Rest of Asia-Pacific Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 6.19 RoW Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
Table 8.1: Accelrys Key Developments
Table 8.2 Certara Biosimulation Products, 2016
Table 8.3: Certara Key Developments
Table 8.4: Simulation Plus Key Developments
Table 8.5: Dassault Systems Key Developments
Table 8.6: Schrödinger Key Developments
Table 8.7: Advanced Chemistry Development Key Developments
Table 8.8: Chemical Computing Group Key Developments
Table 8.9: Genedata AG Key Developments
Table 8.10: Physiomics AG Key Developments

【レポートのキーワード】

バイオシミュレーション

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ バイオシミュレーションの世界市場(Biosimulation World Market 2017-2027)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆